Mineralys Therapeutics (MLYS) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Mineralys Therapeutics (NASDAQ: MLYS):

• 10/15/2026 – Mineralys Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Mineralys Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $56.00 price target on the stock.
• 10/11/2026 – Mineralys Therapeutics is now covered by UBS Group. They set a “neutral” rating and a $29.00 price target on the stock.
• 10/11/2026 – Mineralys Therapeutics was upgraded by UBS Group to “hold”.
• 9/11/2026 – Mineralys Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider Eric Warren sold 7,438 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $28.12, for a total value of $209,156.56. Following the sale, the insider owned 38,400 shares of the company’s stock, valued at $1,079,808. This trade represents a 16.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total transaction of $85,740.00. Following the transaction, the director owned 6,200 shares of the company’s stock, valued at $177,196. This trade represents a 32.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 199,365 shares of company stock worth $5,461,854 over the last quarter. 18.94% of the stock is currently owned by insiders.

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company’s research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys’ lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.